An observational study in Diabetes Mellitus, Type 2 and Systemic Arterial Hypertension, sponsored by Instituto epHealth. Active, not recruiting at 11 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Instituto epHealth · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 36 open to participants now, 45 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one has the largest planned enrollment of the 22 observational ones that give a count, is one of 4 that started in 2025, is one of 22 observational ones, reaches primary completion later than 18 of the 44 other live ones, and was the 317th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →36 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Sao Francisco · Sites in Brazil
Ages 40–80 · Healthy volunteers
Eli Lilly and Company · Sites in Brazil, United States, China and 7 more countries
Ages 18+
AstraZeneca · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 7 more countries
Ages 10–18
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 151 · Phase 4 37
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40,000 is above the median of 300 across 1,744 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 326 across the 295 interventional studies, 370 across the 22 observational. Of the 239 that completed or were terminated, 116 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 317 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Instituto epHealth as lead sponsor.
Instituto epHealth has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07463859University of Sao PauloEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus | 2027-01-31 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
| NCT06735859Federal University of São PauloEating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss | 2027-06 |
| NCT07846319epHealthEvaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study evaluates the implementation of the epCertify system with the Hiperdia Care Pathway in Primary Health Care, measuring its impact on the clinical control of hypertension and diabetes and on the quality of care records. Systemic arterial hypertension and diabetes mellitus are among the main public health problems in Brazil, due to their high prevalence, chronic nature, and contribution to outcomes such as stroke, renal failure, myocardial infarction, and non-traumatic amputations. In 2021, 26.3% of the Brazilian adult population reported a medical diagnosis of hypertension and about 20 million Brazilians were living with diabetes. In the second four-month period of 2021, only 43.7% of registered hypertensive patients and 46.2% of registered diabetic patients were followed up with a consultation in the last 12 months, which suggests a structural weakness in current care models. epCertify is an integrated digital solution aimed at the longitudinal monitoring of these conditions in PHC. It operates as cloud-based middleware that consolidates and qualifies existing databases (Citizen's Electronic Health Record, e-SUS Atenção Básica, and the National Registry of Health Establishments) and includes automated validation of registrations based on CPF and clinical criteria, real-time monitoring dashboards with alerts for blood pressure control and glycated hemoglobin requests, integration with e-SUS and RNDS, and team training. The system was previously deployed in the participating municipalities under the Juntos pela Saúde project, an initiative of BNDES in partnership with UMANE and managed by IDIS, through technical-scientific cooperation agreements with Instituto epHealth. The deployment involved registration validation, activation of digital tools, team training, and the start of use in clinical routine, and was completed at the time this evaluation began. This is a mixed-methods, observational study, with a retrospective and prospective approach, conducted in 10 Brazilian municipalities in the states of Rio Grande do Norte, Bahia, Maranhão, Paraíba, and Pernambuco, with an estimated population of 220,649 inhabitants, of whom about 158,867 are 18 years of age or older. The analysis follows the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance) and uses anonymized secondary data from integrated clinical and administrative databases. Eligible participants are adults aged 18 years or older, with an active registration in the epCertify system, residing in the participating municipalities, and with a diagnosis of hypertension (ICD-10 I10-I15) and/or diabetes mellitus (ICD-10 E10-E14) recorded in PEC or identified via a community health worker. Individuals with insufficient clinical data for analysis are excluded. The study adopts a census-based analysis approach, covering all eligible individuals in the databases of the participating municipalities, estimated at between 32,000 and 40,000.
The primary outcomes are blood pressure measurement in Hiperdia patients and glycated hemoglobin requests. The secondary outcomes include good care practice scores for people with hypertension and with diabetes, blood pressure measurement in hypertensive and in diabetic patients, blood pressure control, glycemic control, medical consultations, prescription of antihypertensive and antidiabetic drugs, weight and height measurement, diabetic foot examination, and home visits by community health workers.
The observation period after system deployment is 6 months, compared with the period prior to deployment. The hypothesis is that the implementation of epCertify significantly increases the proportion of patients with up-to-date blood pressure and glycated hemoglobin records relative to the prior period. The methodological approach is a before-and-after design, with the individual as the main unit of analysis and aggregations by municipality or basic health unit. Paired comparison tests, univariate and multivariate logistic regression, and hierarchical mixed-effects models with repeated measures are planned, as well as subgroup analyses and analyses of agreement between community health worker records and the electronic health record using Cohen's Kappa. All data come from routine databases and undergo de-identification before any analysis, with removal of direct identifiers, anonymization through irreversible hashing, and storage in a dedicated cloud instance with restricted access and audit logging. The protocol provides for a request for waiver of the individual Informed Consent Form, based on the logistical unfeasibility of obtaining consent, the absence of risk to individuals, and the exclusive use of anonymized data, with institutional authorization through a Technical Cooperation Agreement executed by the local health authority.
Background and rationale: Systemic arterial hypertension (SAH) and diabetes mellitus (DM) are among the main public health problems in Brazil, due to their high prevalence, chronic nature, and contribution to outcomes such as stroke, renal failure, myocardial infarction, and non-traumatic amputations In 2021, 26.3% of the Brazilian adult population reported a medical diagnosis of hypertension, an increase of 3.7% over 15 years, and about 20 million Brazilians were living with diabetes. In the same year, deaths attributable to these two conditions increased by 15% compared with the 2015 to 2019 period. Premature mortality from diabetes, between 30 and 69 years of age, reached 41% in 2018. There is a mismatch between the volume of individuals with these conditions and their effective incorporation into Primary Health Care (PHC) routines. In the second four-month period of 2021, only 43.7% of registered hypertensive patients and 46.2% of registered diabetic patients were followed up with a consultation in the previous 12 months. Brazilian PHC relies on e-SUS Atenção Básica (e-SUS AB), the Citizen's Electronic Health Record (PEC), and the National Health Data Network (RNDS). The Hiperdia program, aimed at the continuous monitoring of patients with hypertension and diabetes, faces challenges in modernizing systems, integrating with remote monitoring technologies, and expanding access to diagnostic tests. The absence of a validated and standardized model for data certification and interoperability in PHC represents a weakness for the consolidation of resolutive, continuous, and equitable chronic care, and prevents programs such as Hiperdia and Previne Brasil from reaching their full potential.
The epCertify system: epCertify is an integrated digital solution for the longitudinal monitoring of hypertension and diabetes in PHC. It works as cloud-based middleware that consolidates and qualifies existing databases, linking CHWs, PEC, e-SUS AB, and RNDS in an interoperable platform oriented toward the Hiperdia care pathway, generating indicators compatible with the criteria of the Ministry of Health (Brasil 360) and the RNDS. Its main components are direct connectors with PEC and e-SUS AB, which allow continuous ingestion of diagnoses (ICD-10), prescriptions, blood pressure measurement records, and glycated hemoglobin (HbA1c) requests; integration with CNES, which identifies units, teams, and professionals and allows analysis by team, Basic Health Unit (UBS), and municipality; and a registration validation module, which checks the consistency and completeness of records. Automated validation includes mandatory CPF for those over 18 years of age, verification of key fields against public reference databases, cross-checking with the civil registry to exclude CPFs associated with death, identification of inconsistencies for manual correction, and final validation for synchronization with PEC. The system feeds a monitoring dashboard that allows managers and teams to track, in real time, the validated registration of the target population, assess the coverage of blood pressure measurement and HbA1c requests, monitor indicators of clinical control, consultations, and prescriptions, and identify care barriers and areas with lower performance. It also makes it possible to assess the agreement between the information collected in the field by CHWs and that recorded in PEC.
Objectives: The primary objective is to evaluate the effectiveness of implementing epCertify with the Hiperdia Care Pathway, measuring its impact on the clinical control of hypertension and diabetes, with a focus on the effectiveness and sustainability of the intervention in the real-world context of clinical practice. The secondary objectives are to determine the impact of registration certification on population coverage; to evaluate the change in coverage and clinical control, measured by blood pressure and HbA1c, before and after implementation; and to analyze team adherence to the use of the dashboard and the epCertify Profissionais app.
Design and population: Mixed-methods, observational study, with a retrospective and prospective approach, conducted in 10 Brazilian municipalities in the states of Rio Grande do Norte, Bahia, Maranhão, Paraíba, and Pernambuco. The estimated population is 220,649 people, of whom 158,867 are 18 years of age or older. The expected duration is 12 months and the study phase is not applicable. The analysis follows the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance), using anonymized secondary data from integrated clinical and administrative databases. Included are individuals aged 18 years or older, with an active registration in the epCertify system, residing in the participating municipalities, and with a diagnosis of hypertension (ICD-10 I10-I15) and/or diabetes mellitus (ICD-10 E10-E14) recorded in PEC or identified via CHWs. Individuals with insufficient clinical data for analysis are excluded. The exposure factor is the diagnosis of hypertension or diabetes.
Prior implementation and stakeholders: The system was already deployed in the participating municipalities at the start of the study, in active use in clinical routine, under the Juntos pela Saúde project, an initiative of BNDES in partnership with UMANE and managed by IDIS, through technical-scientific cooperation agreements with Instituto epHealth. The deployment included local extraction of PEC and e-SUS AB data by municipal technical teams, application of automated registration validation routines, elimination of duplicates, standardization of variables, and consistency auditing, followed by making the monitoring dashboards available to the municipalities. Knowledge mobilization involved initial team training, ongoing remote technical support, periodic operational reports, and horizontal exchanges between municipalities. In the registration certification cycle, the Municipal PHC Coordination planned and supervised the deployment; the Municipal Information Officers extracted the data and coordinated corrective actions; the Health Unit Coordination supported the Family Health Strategy (FHS) teams in correcting data and promoted use of the dashboard; and Instituto epHealth processed the data and activated the digital tools. In the clinical cycle, PHC nurses carry out risk stratification and clinical updates in PEC, FHS physicians manage clinical conduct according to national protocols, and CHWs conduct home visits focused on qualified data collection and alerting to risk situations.
Observation period: The observation period after system deployment is 6 months. Data from the period prior to deployment are used for comparison.
Outcomes: The primary outcomes are blood pressure measurement in Hiperdia patients, measured as the proportion of registered patients with at least one blood pressure record in the previous 6 months, and glycated hemoglobin requests, measured as the proportion of registered diabetic patients with at least one HbA1c request in the previous 6 months. The secondary outcomes include the good care practice scores for people with hypertension and with diabetes; blood pressure measurement in hypertensive and in diabetic patients; proportion of hypertensive and diabetic patients with controlled blood pressure, defined as values below 140/90 mmHg; proportion of diabetic patients with controlled glycated hemoglobin, defined as a value below 7.0%; medical consultations in hypertensive, diabetic, and Hiperdia patients in the previous 6 months; prescription of antihypertensive and antidiabetic drugs; in-person measurement of weight and height in the previous 12 months; diabetic foot examination in the previous 12 months; and at least two CHW visits in the previous 12 months.
Good practice indicators: For hypertension, the indicator sums four good practices defined by the Ministry of Health, each worth 25 points, totaling 100: at least one in-person or remote consultation with a physician or nurse in the previous 6 months; at least one blood pressure measurement record in the previous 6 months; at least one simultaneous record of weight and height in the previous 12 months; and at least two home visits by a CHW or Health Surveillance Agent (TACS), at least 30 days apart, in the previous 12 months.
For diabetes, the indicator sums six good practices, totaling 100 points: consultation with a physician or nurse in the previous 6 months (20 points); blood pressure measurement in the previous 6 months (15 points); weight and height record in the previous 12 months (15 points); two home visits by a CHW or TACS, at least 30 days apart, in the previous 12 months (20 points); glycated hemoglobin record, requested or evaluated, in the previous 12 months (15 points); and foot assessment record in the previous 12 months (15 points).
Both scores are presented in three formats: sum of points; possibilities score, which indicates how many of the eligible good practices were fulfilled; and an all-or-nothing model, in which the indicator is considered fulfilled only if all eligible practices were met.
Variables by RE-AIM dimension: For reach, the following are assessed: total population followed up, registered population aged 18 years or older, percentage registered relative to the IBGE estimate, validated registration rate, number of individuals with SAH, with DM, and with both conditions, age and gender distribution, education level, socioeconomic status, population covered by CHWs, number of active UBSs, population served per UBS, number of professionals and CHWs per UBS, and FHS coverage. For effectiveness, the following are assessed: care process indicators (blood pressure measurement in SAH and in DM, HbA1c requests and records, medical and nursing consultations, prescriptions, weight and height measurement, BMI, diabetic foot examination, and home visits) and clinical outcomes (systolic and diastolic blood pressure, blood pressure control, HbA1c, glycemic control, and means per UBS). For implementation, the following are assessed: number of professionals active on the dashboard, defined as a login in the last 30 days, average frequency of use, records integrated into e-SUS and RNDS, valid and complete CPFs, registration discrepancies, and automatic and manual corrections. For maintenance, the following are assessed: continued use after 6 months, measured by the number of municipalities active at the end of the period, and the average time of dashboard use.
Hypothesis and statistical power: The hypothesis is that the implementation of epCertify significantly increases the proportion of patients with up-to-date blood pressure and glycated hemoglobin records, compared with the prior period. The study is conducted under a census-based analysis approach, covering all individuals aged 18 years or older with a diagnosis of hypertension and/or diabetes in the databases of the 10 municipalities. Considering an expected average prevalence of 20% to 25%, the target population is estimated at 32,000 to 40,000 individuals. Even without a traditional sample size calculation, statistical power is equal to or greater than 90% for comparing proportions pre- and post-implementation, especially for differences of 10 percentage points or more, with two-sided significance of 5%.
Statistical analysis plan: A detailed statistical analysis plan will be developed as a component of the study documents. The approach is a before-and-after design, comparing indicators between the pre-intervention period, as the baseline, and the 6-month post-implementation period. The main unit of analysis is the individual, with aggregations by municipality or UBS. Univariate descriptive analyses are performed to characterize the population in terms of sociodemographic, clinical, and contextual variables. To assess changes between periods, the chi-square test or McNemar's test is applied for categorical variables, and the paired t-test or Wilcoxon test for continuous variables, depending on the distribution. The main clinical outcomes, blood pressure control and glycemic control, are treated as binary variables, with univariate and multivariate logistic regression models to estimate odds ratios adjusted for age, sex, municipality, health team, and follow-up time. Since the data have a hierarchical structure, with measurements nested within patients, patients within health units, and units within municipalities, mixed-effects models with repeated measures over time are used. The multilevel logistic model is applied to dichotomous outcomes, and the models for quantitative outcomes are defined according to the distribution of the random error. Subgroup analyses are planned by age group (18 to 39, 40 to 59, and 60 years or older), by team type, and by level of care coverage of the UBS, in addition to examining interactions between municipality and level of professional adherence to the system. Data quality control is part of the analysis, with quantification of the completeness of clinical records and assessment of the impact of registration certification on reducing inconsistencies. Agreement between the CHW and PEC sources is assessed using Cohen's Kappa or weighted Kappa, raw proportion of agreement, and relative discordance with 95% confidence intervals, and stratified analyses. Quantitative results are triangulated with evidence from qualitative analysis of implementation data, such as interviews with managers and professionals. All analyses adopt a two-tailed significance level of 5%, with 95% confidence intervals, in R and/or Stata.
Data management and protection: All data come from routine databases and undergo de-identification before any analysis. Measures include removal of direct identifiers, such as name, address, telephone number, RG, CPF, CNS, and specific dates; anonymization through secure and irreversible hashing, with segmentation of identifiable and clinical data into separate environments; storage in a dedicated cloud instance, with restricted access control, multi-factor authentication, and full audit logging; and compliance with the LGPD and international practices such as ISO/IEC 27001 and HIPAA. Data from the study population are separated from the rest of the platform database, anonymized in that environment, and transferred to the statistics team only for the variables of interest, following the principle of using the smallest possible amount of data.
Ethical aspects: The study follows Brazilian and international Good Clinical Practice standards, including Law No. 14,874/2024, Resolution No. 466/12 and documents related to the LGPD, CFM Resolution No. 2,614 of April 20, 2022, and the Guidelines for Good Clinical Practice, Amendment 6, Revision 3. There are no physical or biological risks to participants, as there is no direct contact during the conduct of the study. This is a non-interventional observational study using previously collected anonymized data; the potential risk refers to a breach of identity confidentiality, mitigated by the measures described above. The expected benefits relate to better knowledge of the characteristics of the population at cardiovascular risk served in the context of the Family Health Strategy. The protocol provides for a request for waiver of the individual Informed Consent Form, based on three aspects: the practical and logistical unfeasibility of obtaining consent, given that the study covers about 250,000 inhabitants and uses exclusively secondary data already collected and anonymized; the absence of risk to individuals and the exclusive use of anonymized data, supported by Article 11, item II, subparagraph "c" of the LGPD; and the scientific purpose and collective benefit, with results presented exclusively at the aggregate level. The participating municipalities signed a Technical Cooperation Agreement, executed by the local health authority, which confirms institutional authorization for the municipality's participation, authorizes the use of anonymized data exclusively for scientific research purposes, reinforces the commitment to confidentiality and aggregate-level analysis, and ensures that the system's effects are monitored without implying risks or burdens to SUS users or to professionals individually. Before the start of the study, the protocol and other documents must be approved by the Research Ethics Committee of the coordinating center. The investigator must submit partial reports annually and whenever requested, and a final report upon completion. Changes to the protocol must be recorded through an amendment signed by the Principal Investigator, with REC approval prior to implementation.
Funding and governance: The coordination and provision of resources are the responsibility of Instituto epHealth, which manages the human resources necessary for conducting the project. The study is conducted as a scientific evaluation component of the epCertify system already deployed in the participating municipalities through the Juntos pela Saúde project. Instituto epHealth is committed to publishing the results, regardless of their nature.
Adults aged 18 years or older with an active registration in the epCertify system, residing in one of the 10 participating municipalities, with a recorded diagnosis of hypertension (ICD-10 I10-I15) and/or diabetes mellitus (ICD-10 E10-E14) in the electronic health record or identified by community health workers. The study uses a census approach, including all eligible individuals in the participating municipal databases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: epCertify system implementation
Other: epCertify system implementation
Other: epCertify system implementation
Digital platform for registry certification and monitoring of the Hiperdia care line, deployed in participating municipalities prior to the start of this evaluation. Includes automated registry validation, real-time monitoring dashboards for primary care teams, integration with e-SUS AB and RNDS, and training of primary care teams. The study observes the effects of this deployment using routinely collected data; no intervention is assigned by the study.
Blood pressure measurement among Hiperdia patients
Proportion of registered Hiperdia patients with at least one blood pressure measurement recorded in the electronic health record in the previous 6 months
Time frame: Baseline period and 6-month post-implementation period.
HbA1c test ordering among patients with diabetes
Proportion of registered patients with diabetes with at least one HbA1c test ordered in the previous 6 months
Time frame: Baseline period and 6-month post-implementation period.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Oct 2026, 9 months.
Of 434 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's 9 months is below that.
Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.